Among drugs that act on the androgen pathway, there are several distinct approaches. Finasteride and dutasteride reduce how much DHT gets made in the first place. Antagonists such as KX-826 and clascoterone occupy the androgen receptor and physically block DHT from binding to it, while the receptor itself stays intact. GT20029 takes a more unusual approach still, targeting the receptor for degradation rather than blocking it.

GT20029 is built on PROTAC (proteolysis-targeting chimera) technology, a class of molecule designed to tag a target protein for the cell's own disposal machinery, the ubiquitin-proteasome pathway, marking it for destruction rather than simply occupying it. Applied to the scalp, this is intended to reduce the number of functioning androgen receptors in hair follicle and sebaceous gland tissue directly, rather than leaving the receptor in place and competing with DHT for it. Kintor designed GT20029 to retain activity in the treated tissue while limiting systemic exposure. Kintor describes it as among the first topical PROTAC compounds to reach this stage of clinical development for any indication, not just hair loss.

Unlike most compounds at this stage, the full trial results here have been through peer review and journal publication, not just a company press release. The 0.5% and 1.0% doses tested in Phase 2 were themselves the product of earlier work: in a DHT-induced mouse model, 0.5%, 1%, and 3% concentrations of GT20029 all showed activity, with the 1% and 3% doses performing comparably to 5% topical minoxidil in that same animal model, a preclinical comparison rather than a human head-to-head test. A subsequent Phase 1 safety trial tested 0.5%, 1.0%, and 2.0% once-daily doses in humans; the two lower doses were better tolerated, providing the basis for carrying 0.5% and 1.0% forward into Phase 2.

TAHC is worth explaining in plain terms, since the numbers involved don't mean much without it. Researchers marked a small, roughly 1cm² circle on the balding area with a semi-permanent ink-dot tattoo so the same patch of scalp could be photographed and compared at every visit, then clipped hairs in that circle short and counted how many were thick, pigmented (non-vellus) hairs rather than the fine, fuzz-like vellus hairs typical of miniaturised follicles. At baseline, the average count across the six groups sat between roughly 105 and 120 non-vellus hairs in that one square centimetre; a healthy, non-balding scalp typically runs higher. A bigger increase in that count over 12 weeks means more non-vellus hairs were present in the treated patch, an objective measure of increased hair density rather than a naked-eye judgement of what looks fuller.

Coverage of this trial has generally reported it as a clean success. More precisely: the study reported a statistically significant treatment effect on its primary endpoint for two of the four active dosing regimens. The other two active arms improved from baseline but weren't reported as significantly different from placebo. That distinction is the detail worth sitting with.

All four active groups showed significant increases in hair count compared with their own starting point (p<0.001 for each), but that within-group comparison isn't the one that demonstrates treatment efficacy in a placebo-controlled trial. The comparison that matters is against the matched placebo group, and there only two of the four cleared significance: 0.5% once daily and 1.0% twice weekly. In concrete terms, the 0.5% once-daily group gained 16.80 non-vellus hairs per square centimetre over baseline against 10.10 for its matched placebo (p=0.032); the 1.0% twice-weekly group gained 11.94 hairs per square centimetre against 4.57 for its placebo (p=0.023). The other two active arms, 0.5% twice weekly and 1.0% once daily, improved from baseline but weren't reported as reaching significance against placebo. On hair width, only one arm stood out: 1.0% twice weekly was the sole dose to show a significant improvement over placebo (0.54 vs -0.02 mm/cm², p=0.011).

The placebo groups also showed real increases in hair count over the 12 weeks, not just a flat baseline. That's another reason the between-group comparison matters more than the raw change from baseline: a treatment that only beats its own starting point hasn't yet shown it beats simply applying something to the scalp daily for three months.

There's also a counterintuitive result buried in the dosing pattern. According to the paper, no clear dose-response trend emerged among the once-daily groups, but a dose-response trend was evident among the twice-weekly groups, meaning 1.0% twice weekly outperformed 0.5% twice weekly in a way that 1.0% once daily didn't clearly outperform 0.5% once daily. That's worth flagging without overreading it: the study wasn't designed to establish a dose-frequency relationship, and this doesn't show that twice-weekly application is inherently more effective than daily application, only that it's what happened in this dataset.

Taken together, 1.0% twice weekly is the only dose that performed strongly on both measures, and it's the dose Kintor has since selected for Phase 3. That's a sensible choice given the data, but it also means the headline "Phase 2 met its primary endpoint" describes the trial as a whole more generously than it describes half of the doses tested within it. Adverse event rates were similar to placebo across all groups, and no treatment-related sexual adverse events were reported.

Kintor is developing GT20029 for AGA and acne in parallel, using the same broad rationale: androgen-receptor signalling contributes to both conditions, although the underlying biology differs. The acne programme is currently a step ahead. Its Phase 2 acne trial read out in August 2025, met its primary endpoint, and Kintor has already selected 0.5% as the Phase 3 dose for that indication. For AGA, Phase 2 data is now published, but a Phase 3 start hasn't been publicly confirmed as of the most recent reporting available.

Kintor has pointed to clascoterone's approval as an acne treatment (marketed as Winlevi) as validation that targeting the androgen receptor in skin works as a general strategy, though clascoterone is an antagonist and GT20029 a degrader, a different mechanism within the same broad target. Kintor's own AR antagonist, KX-826, is considerably further along, already in Phase 3 for AGA in China with patient enrolment completed. Having two AR-targeting compounds with different mechanisms in parallel development gives Kintor a natural head-to-head comparison down the line, though no such trial has been announced.

This article is provided for educational purposes and does not constitute medical or investment advice. GT20029 is an investigational compound not approved for any use by the FDA, MHRA, NMPA, or any other regulatory body. AmpleLab products are unrelated to GT20029 and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.